title: [Conversion Surgery for Initially Unresectable Locally Advanced Pancreatic Cancer Following Gemcitabine plus Nab-Paclitaxel - A Case Report].
abstract: We report a case of unresectable locally advanced pancreatic cancer successfully resected after gemcitabine(GEM)plus nab-paclitaxel(PTX)treatment. A 68-year-old man was referred to our institution with jaundice. We diagnosed pancreatic head cancer using computed tomography(CT)and endoscopic retrograde cholangiopancreatography. We initially diagnosed it as locally advanced unresectable pancreatic cancer because of extensive invasion to the portal vein. GEM plus nab- PTX was administered to the patient as systemic chemotherapy. After 9 courses of chemotherapy, a CT scan revealed that the tumor had significantly reduced in size and range of portal vein invasion. Therefore, we performed pancreaticoduodenectomy with resection of the portal vein and achieved R0 resection. Currently, the patient is alive without recurrence. Therefore, conversion surgery after treatment with GEM plus nab-PTX chemotherapy for unresectable pancreatic cancer should be considered.
authors.affiliation: Dept. of Surgery, Kitasato University School of Medicine.
authors.forename: Shuji
authors.initials: S
authors.lastname: Nakamoto
authors.forename: Ryo
authors.initials: R
authors.lastname: Nishiyama
authors.forename: Takayoshi
authors.initials: T
authors.lastname: Kaneda
authors.forename: Mitsuo
authors.initials: M
authors.lastname: Yokota
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kawamata
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Tajima
authors.forename: Takashi
authors.initials: T
authors.lastname: Kaizu
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Kumamoto
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yamauchi
authors.forename: Kosuke
authors.initials: K
authors.lastname: Okuwaki
authors.forename: Tomohisa
authors.initials: T
authors.lastname: Iwai
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Imaizumi
authors.forename: Erina
authors.initials: E
authors.lastname: Suzuki
authors.forename: Atsuko
authors.initials: A
authors.lastname: Hara
authors.forename: Masaaki
authors.initials: M
authors.lastname: Ichinoe
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Kida
authors.forename: Masahiko
authors.initials: M
authors.lastname: Watanabe
mesh_terms: D000368:Aged; D000418:Albumins / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D008297:Male; D020360:Neoadjuvant Therapy; D017239:Paclitaxel / Q000008:administration & dosage; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D016577:Pancreaticoduodenectomy; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: C520255:130-nm albumin-bound paclitaxel; D000418:Albumins; D003841:Deoxycytidine; D017239:Paclitaxel; D000093542:Gemcitabine